Clinical Trial Search

Primary: Total Number of Gd-Enhancing T1-Weighted MRI Lesions Per Scan Averaged During Weeks 12, 16, 20, and 24 — 1.819; 0.710; 1.237; 1.477 lesions per scan

Primary: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16 — 0.9; 3.0 lesions — p=<0.001

Primary: Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening…

Primary: Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period — 74.8 Percentage of Participants

Primary: Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio…

Primary: Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period — 48.1 Percentage of Participants

Primary: Annualized Relapse Rate (ARR) — 0.091; 0.178 relapses per participant-years — p=0.0022

Primary: Placebo-Controlled Phase: Time to Confirmed Disease Progression (CDP) Confirmed After At Least 3 Months (Number of Participants With CDP After At Least 3 Months) — 73…

Primary: Change From Baseline in Patient-reported Treatment Satisfaction — 19.57; 5.83 score on a scale

Primary: Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain — 5.6; 0.6; 0.2; 6.9 lesions — p=<0.0001

Primary: Time From Baseline to First Multiple Sclerosis Relapse (in Weeks) — 35.5; 40.9 weeks — p=0.1384

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Cumulative Number of Combined Unique Active Lesions — 0.23; 0.02; 3.84; 3.08 lesions

Primary: Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period — 0.54; 0.67 Confirmed relapses — p=0.0024

Primary: Annualized Relapse Rate (ARR) — 0.076; 0.188 relapses per participant-years — p=<0.0001

Primary: Annualized Relapse Rate (ARR) at 1 Year — 0.397; 0.288; 0.256 relapses per person-years — p=0.0114

Primary: Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) — 310; 182; 97 days — p=<0.001

Primary: Number of Participants With Any Adverse Event — 8; 10; 7; 3 participants

Primary: Percentage of Relapse-free RMS Subjects — 66.3 percentage of subjects

Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks — 0.292; 0.156 relapses/participant year of treatment — p=<0.0001

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 100; 12; 0 Participants

Primary: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks In Double Blind Period — 0.290; 0.155 relapses/participant year of…

Primary: The Number of New or Recurrent Gd-enhancing Lesions That Appear on Brain T1-weighted MRI — 0.12 lesions

Primary: Annualized Qualifying Relapse Rate — 0.15; 0.14; 0.33 relapses per year — p=<0.001

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Measure: Number of Subjects With Adverse Events, Number of Abnormalities in Safety Assessments — 12; 8 participants

Primary: Estimated Annualized Aggregate Relapse Rate (ARR) — 0.16; 0.18; 0.40 Relapses per year

Primary: Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression — 0.331; 0.505 confirmed relapses…

Primary: Number of Days Until First On-study Relapse — NA; 103 days — p=0.125

Primary: Safety and Tolerability — 10; 9; 10; 9 Participants with at least one TEAE